Minoryx: Significant Phase 3 results for the Belgian-Spanish biotech company Minoryx

Minoryx has completed a Phase 3 trial with its drug candidate for a neurodegenerative orphan disease and the results are significant. The only downside is that the primary endpoint was not met. It was the evaluation of a change from baseline in a 6-minute walk test. Minoryx hopes that this will not be a barrier to the further process of bringing its treatment to market, given the other important benefits that have been achieved.